Sonodynamic therapy using sonodynamically activated coordination complexes of transition metals as sensitizing agents

11813,330

17/192569

March 04, 2021

A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a sonosensitizing compound containing at least one transition metal with three bidentate ligands; and (b) exposing the sonosensitizing compound in the organism to ultrasound, wherein the ultrasound is effective to activate the sonosensitizing compound to destroy at least one of the cells and the microorganisms in the organism. The ultrasound is preferably used in conjunction with electromagnetic therapies comprising photodynamic therapy, low-level laser therapy, and radiation therapy. The ultrasound is preferably administered at a duty cycle in the range from 5% to 95% at a power density of 10 W/cm2 and a frequency in the range from 10 Hz to 10 MHz.

Theralase Technologies, Inc. (Toronto, CA)

THERALASE TECHNOLOGIES, INC. (Toronto, CA)

1. A method for damaging a target material in an organism, said method comprising: administering to the organism a composition comprising a sonosensitizing compound having the formula (I): [chemical expression included] including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: M is osmium or ruthenium; X is selected from the group consisting of Cl − , PF 6 − , Br − , BF 4 − , ClO 4 − , CF 3 SO 3 − , and SO 4 −2 ; n=0, 1, 2, 3, 4, or 5; q is independently at each occurrence 0, 1, or 2; y is independently at each occurrence 0, 1, or 2; z is independently at each occurrence 1, 2, or 3; q+y+z=3; Lig 1 is a bidentate ligand that at each occurrence is each independently selected from the group consisting of [chemical expression included] Lig 2 is a bidentate ligand that at each occurrence is each independently selected from the group consisting of [chemical expression included] Lig 3 is a bidentate ligand that is [chemical expression included] R 1 is selected from the group consisting of [chemical expression included] u is an integer from 1 to 10; R 2a , R 2b , R 2c , R 2d , R 2e , R 2f , R 2g , R 2h , R 2i , R 2j , R 2k , and R 2l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 3-7 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , SO 3 H, sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h ,R 3i , R 3j , R 3k , and R 3l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, optionally substituted phenyl, and CO 2 R 8 , R 4a , R 4b , and R 4c at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 4a and R 4b at each occurrence on a thiophene ring are taken together with the atom to which they are bound to form an optionally substituted ring having from 6 ring atoms containing 2 oxygen atoms; R 5 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 6 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 7 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; and R 8 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; and exposing the sonosensitizing compound to an activating energy, wherein the target material comprises at least one of cells and microorganisms, and the activating energy comprises ultrasound effective to trigger the sonosensitizing compound to damage the target material.

2. The method of claim 1 , wherein the target material comprises hyperproliferating cells in the organism, and the method is effective to inhibit proliferation of the hyperproliferating cells in the organism or to destroy the hyperproliferating cells in the organism.

3. The method of claim 1 , wherein the target material comprises microorganisms selected from the group consisting of bacteria, viruses, and fungi, and the method is effective to destroy the microorganisms.

4. The method of claim 1 , wherein the organism is a human.

5. The method of claim 1 , wherein the composition is administered by topical, oral, buccal, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, vaginal, ophthalmic, pulmonary, rectal or extracorporeal routes.

6. The method of claim 1 , wherein the composition is pharmaceutically acceptable and further comprises at least one pharmaceutically acceptable carrier, excipient, or diluent.

7. The method of claim 1 , wherein the composition further comprises a metal-binding glycoprotein, a glycated or non-glycated form thereof.

8. The method of claim 7 , wherein the metal-binding glycoprotein is transferrin.

9. The method of claim 1 , wherein the ultrasound is administered in a continuous fashion at 100% duty cycle.

10. The method of claim 9 , wherein the ultrasound is administered at a power of 0.01 W/cm 2 to 10 W/cm 2 .

11. The method of claim 1 , wherein the ultrasound is administered in a pulsed fashion at a duty cycle between 5% and 95%.

12. The method of claim 11 , wherein the ultrasound is administered at a power of 10 W/cm 2 and frequency between 10 Hz to 10 MHz.

13. The method of claim 1 , wherein the sonosensitizing compound is administered in combination with electromagnetic radiation.

14. The method of claim 13 , wherein the combination of the sonosensitizing compound and the electromagnetic radiation is synergistically effective.

15. The method of claim 14 , wherein the electromagnetic radiation comprises infrared or visible light.

16. The method of claim 15 , wherein light is emitted from a laser.

17. The method of claim 14 , wherein the electromagnetic radiation comprises ionizing radiation.

18. A method for damaging a target material in an organism, said method comprising: administering to the organism a composition comprising a sonosensitizing compound having a structure selected from the group consisting of: [chemical expression included] including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and exposing the sonosensitizing compound to an activating energy, wherein the target material comprises at least one of cells and microorganisms, and the activating energy comprises ultrasound effective to trigger the sonosensitizing compound to damage the target material.

19. The method of claim 18 , wherein the ultrasound is administered: (a) in a continuous fashion at 100% duty cycle at a power of 0.01 W/cm 2 to 10 W/cm 2 ; or (b) in a pulsed fashion at a duty cycle between 5% and 95% at a power of 10 W/cm 2 and a frequency between 10 Hz to 10 MHz.

20. The method of claim 19 , wherein the composition further comprises transferrin and at least one pharmaceutically acceptable carrier, excipient, or diluent.

21. The method of claim 20 , wherein the sonosensitizing compound has the following structure: [chemical expression included] or is a hydrate, solvate, pharmaceutically acceptable salt, prodrug or complex thereof.

22. The method of claim 20 , wherein the sonosensitizing compound has the following structure: [chemical expression included] or is a hydrate, solvate, pharmaceutically acceptable salt, prodrug or complex thereof.

5632970 May 1997 Sessler et al.
6498945 December 2002 Alfheim et al.
8318794 November 2012 Wang et al.
8758725 June 2014 Sharma et al.
9220718 December 2015 Park et al.
20030082101 May 2003 Taylor et al.
20100262115 October 2010 Madiyalakan et al.
20150374216 December 2015 Chae
20160039854 February 2016 McFarland
20170304648 October 2017 Mandel et al.
102670512 September 2012
9852610 November 1998
2012143739 October 2012

English Abstract for CN 102670512 A (2012). cited by applicant
Chen et al. (2012). Use of a novel sonosensitizer in sonodynamic therapy of U251 glioma cells in vitro. Experimental and Therapeutic Medicine, 3, 273-278. cited by applicant
Li et al. (2015). Pulsed high intensity focused ultrasound (pHIFU) enhances delivery of doxorubicin in a preclinical model of pancreatic cancer. Cancer Res., 75(18), 3738-3746. cited by applicant
Monro et al. (2019). Transition metal complexes and photodynamic therapy from a tumor-centered approach: challenges, opportunities, and highlights from the development of TLD1433. Chem Rev., 119(2), 797-828. cited by applicant
Wan et al. (2016). Recent advances of sonodynamic therapy in cancer treatment. Cancer Biol Med, 13(3), 325-338. cited by applicant
Wang et al. (2014). Ultrasound and microbubble guided drug delivery: mechanistic understanding and clinical implications. Curr Pharm Biotechnol, 14(8), 743-752. cited by applicant
Chen et al. (2006). Using Nanoparticles to Enable Simultaneous Radiation and Photodynamic Therapies for Cancer Treatment. Journal of Nanoscience and Nanotechnology, vol. 6, 1159-1166. cited by applicant
Cheng et al. “Bottom Up Synthesis of Metal Ion Doped WS2 Nanoflakes for Cancer Theranostics.” ACS Nano. Nov. 24, 2015;9(11):11090 101. doi: 10.1021/acsnano.5b04606. Epub Oct. 9, 2015). cited by applicant
Deng et al., “Rational Design of Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing p53 Activation. ChemMedChem.” Jun. 2015;10(6):991-8. doi: 10.1002/cmdc.201500127. Epub Apr. 27, 2015). cited by applicant
Sazgarnia et al. (2013). In vitro survival of MCF-7 breast cancer cells following combined treatment with ionizing radiation and mitoxantrone-mediated photodynamic therapy. Photodiagnosis and photodynamic therapy, 10(1), 72-78. cited by applicant

edspgr.11813330